A detailed history of Alliancebernstein L.P. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 217,294 shares of RXRX stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
217,294
Previous 217,294 -0.0%
Holding current value
$1.34 Million
Previous $1.63 Million 12.15%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $538,387 - $736,162
73,250 Added 50.85%
217,294 $1.63 Million
Q1 2024

May 14, 2024

SELL
$9.13 - $15.52 $610,541 - $1.04 Million
-66,872 Reduced 31.71%
144,044 $1.44 Million
Q4 2023

Feb 14, 2024

BUY
$5.09 - $10.79 $243,271 - $515,697
47,794 Added 29.3%
210,916 $2.08 Million
Q3 2023

Nov 14, 2023

SELL
$6.59 - $15.86 $959,108 - $2.31 Million
-145,540 Reduced 47.15%
163,122 $1.25 Million
Q1 2023

May 15, 2023

SELL
$6.42 - $9.64 $526,074 - $789,930
-81,943 Reduced 20.98%
308,662 $2.06 Million
Q4 2022

Feb 14, 2023

SELL
$7.16 - $12.7 $20.4 Million - $36.2 Million
-2,846,739 Reduced 87.93%
390,605 $3.01 Million
Q3 2022

Nov 15, 2022

SELL
$7.83 - $13.6 $2.85 Million - $4.95 Million
-363,616 Reduced 10.1%
3,237,344 $34.4 Million
Q2 2022

Aug 15, 2022

BUY
$5.04 - $9.26 $1.11 Million - $2.04 Million
220,242 Added 6.51%
3,600,960 $29.3 Million
Q1 2022

May 13, 2022

BUY
$6.16 - $18.03 $3.11 Million - $9.1 Million
504,899 Added 17.56%
3,380,718 $24.2 Million
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $20 Million - $27 Million
1,236,478 Added 75.43%
2,875,819 $49.3 Million
Q3 2021

Nov 10, 2021

BUY
$19.03 - $41.33 $6.46 Million - $14 Million
339,419 Added 26.11%
1,639,341 $37.7 Million
Q2 2021

Jul 30, 2021

BUY
$18.0 - $37.42 $23.4 Million - $48.6 Million
1,299,922 New
1,299,922 $47.4 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.12B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.